One thing about surprisingly strong clinical readouts is that investors and physicians are all the more apt to go over a subsequent presentation of the data with a fine-toothed comb looking for warts or other imperfections. Such is the position Amarin finds itself in ahead of the big reveal for detailed findings from REDUCE-IT to be presented on November 10 at the American Heart Association (AHA) meeting after the top-line results for Vascepa (icosapent ethyl) blew away expectations.
To provide FirstWord readers with rapid feedback on whether a more granular look at REDUCE-IT were equally as impressive and what the impact on prescribing patterns will be, we are hosting an expert call with a key opinion leader (KOL) on November 12.
Key topics that will be discussed during the call include, among other things… what are the most important takeaways from the data presentation; were there any surprises – good or bad; did you come away thinking Vascepa’s performance in REDUCE-IT was more or less impressive than at first blush; how will the findings impact use of Vascepa going forward; does this strengthen or weaken Amarin’s claims that Vascepa offers something unique from other fish oil products?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the commercial prospects for Vascepa and other dyslipidaemia drugs.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.